Jennifer Ann Woyach MD

Dr. Woyach is a Professor in the Division of Hematology at The Ohio State University (OSU) in Columbus, Ohio, with a focus on translational research in chronic lymphocytic leukemia (CLL). Though the majority of her time is dedicated to research, which includes laboratory and clinical investigation, she also is the clinical leader of the CLL group at OSU.

Dr. Woyach is the principal investigator for multiple early-stage clinical trials investigating novel targeted therapies for CLL and other hematologic malignancies, and mentors junior faculty members in the development and conduct of Phase I studies. She is chair of the intergroup Phase III study A041202, which investigates chemoimmunotherapy versus targeted therapy as initial treatment for older adults with CLL.

Dr. Woyach’s laboratory interests include experimental therapeutics in CLL with a current focus on signaling pathways and kinase inhibition. Most of her work has focused on BTK inhibitors, resistance mechanisms associated with BTK inhibitors, and strategies to overcome resistance. Additionally, Dr. Woyach leads preclinical and clinical endeavors to identify risk factors for the development of resistance to BTK inhibitors and to explore novel pathways to prevent or circumvent resistance.